Medical & Scientific News

Filter:

Assessing Bleeding Symptoms in Pediatric Patients With Generalized Joint Hypermobility 

The Ehlers-Danlos syndromes (EDS) are known to be associated with increased bleeding symptoms, including easy...

Neurodiversity Celebration Week

Neurodiversity Celebration Week is a worldwide initiative that challenges stereotypes and misconceptions about neurological differences,...

Long Covid Awareness Day

March 15, 2023, is the first International Long Covid Awareness Day.   Many people in the...

Non-surgical assessment and management of upper cervical instability (UCI)

We are aware of the challenges globally around finding expert help for upper cervical instability...

Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS

With a heavy heart, we report that Aytu Biopharma, following a corporate review, has announced...

Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome

The specialty pharmaceutical company,  AytuBio Pharma, announced the initiation of the global Phase 3 PREVEnt...

Pregnancy, Childbirth, and Postnatal Care in EDS and HSD

A small number of studies have looked at the challenges the Ehlers-Danlos syndromes (EDS) and...

Aytu BioPharma Announces PREVEnt Trial Start Planned for Late 2022 or Early 2023

The specialty pharmaceutical company,  AytuBio Pharma, announced this week that it anticipates the PREVEnt trial will...

Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe

The specialty pharmaceutical company, Aytu BioPharma, Inc. (Nasdaq: AYTU), announced this week that the European...

Research Study Update: Muscle Strength and Physical Functioning

New research has been published that studied “Muscle Strength, Muscle Mass and Physical Impairment in...

Funded Research Study Update: Prof. Marina Colombi

The Ehlers-Danlos Society is delighted to have provided funding as part of the Molecular Studies...

Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome

The specialty pharmaceutical company, Aytu BioPharma, Inc. (Nasdaq: AYTU), announced this week that it has received U.S. Food...

Sign up to The Ehlers-Danlos Society bi-weekly newsletter